Committed to metabolic health

Frank Morich has more than 35 years of experience in the biopharmaceutical industry. Before joining Aphaia, he served as Chief Commercial Officer and Executive Vice President, International Operations on the Board of Management at Takeda Pharmaceuticals. Prior to this, Frank served as Chief Executive Officer of NOXXON Pharma AG, and Chief Executive Officer and member of the board of directors of Innogenetics N.V. Frank previously held several positions at Bayer, including as a member of the Board of Management of Bayer AG, Head of Global Product Development and Head of Research and Development. Frank holds a medical degree and a doctorate from the University of Marburg, where he specialized in immunology with a focus on monoclonal antibodies. He served as a military physician before moving to the industry.

Steffen-Sebastian Bolz is a scientist, physician and entrepreneur. He is a Co-Founder of Aphaia Pharma AG and Founder and Chief Scientific and Medical Officer at Qanatpharma AG. Steffen-Sebastian holds a full professorship at the University of Toronto, is a Principal Investigator at the Ted Rogers Centre for Heart Research and is Director of the Toronto Centre for Microvascular Medicine. His research program has contributed novel signaling paradigms, methodological advancements and validated innovative molecular/therapeutic targets in the emerging field of microvascular medicine. Steffen-Sebastian holds a medical degree and a doctorate from the universities of Lübeck and Munich, Germany.

Günter Jucho has a longstanding track record of success in corporate finance and management and is responsible for finance operations as a member of the board of Aphaia Pharma AG. He started his career with an engineering company and has been the co-founder of a print-advertising company responsible for international sales. Later, Günter was the country manager for a renowned German infant food producer. After that, he founded Jucho & Coll, a company specializing in financing medium-sized growth companies. Günter has been engaged in various high-profile entrepreneurial networking organizations and is highly connected to various industries and investment organizations. Recently, he shifted his focus to the corporate finance matters of growth companies in the life science sector. Günter holds a master of business administration from the University of Munster, Germany.